



Republic of the Philippines
Department of Health

CENTRAL OFFICE BIDS AND AWARDS COMMITTEE

MINUTES OF PRE-BIDDING CONFERENCE 20 NOVEMBER 2019, 10:00 AM COBAC CONFERENCE ROOM

Reference No.	Project Title	ABC (PhP)
IB No. 2020-068	Procurement of Betamethasone and Prednisone	2,083,602.00
IB No. 2020-069	Procurement of Diloxanide	1,585,980.00
IB No. 2020-070	Procurement of Fusidate Sodium/Fusidic Acid	4,878,783.20
IB No. 2020-071	Procurement of Ketoconazole and Itraconazole	4,617,538.00
IB No. 2020-072	Procurement of Oral Rehydration Salts	6,738,105.00
IB No. 2020-040	Procurement of Polyvalent Pneumococcal Vaccine	201,200,000.00
IB No. 2020-061	Procurement of Influenza Polyvalent Vaccine	736,000,000.00

I. CENTRAL OFFICE BIDS AND AWARDS COMMITTEE (COBAC) – A

A. ATTENDEES:

- | | | | |
|----|-------------------------------|---|------------------|
| 1. | Asec. Nestor F. Santiago, Jr. | - | Chairperson |
| 2. | Dir. Mar Wynn C. Bello | - | Vice-Chairperson |
| 3. | Dr. Aleli Annie P. Sudiacal | - | Regular Member |
| 4. | Dr. Ma. Soledad Q. Antonio | - | Regular Member |
| 5. | Dr. Allan A. Evangelista | - | Alternate Member |

ABSENT:

- | | | | |
|----|--------------------------|---|----------------|
| 1. | Dir. Leonita P. Gorgolon | - | Regular Member |
|----|--------------------------|---|----------------|

B. COBAC-A SECRETARIAT:

1. Ms. Abegail C. Tigas
2. Ms. Rowena G. Juan
3. Ms. Jenica Lynne S. Villarosa
4. Ms. Janine G. Eumague
5. Ms. Carmelyn M. Manahan
6. Mr. Kayeron E. Canona
7. Ms. Jackie Lou Dimatulac
8. Ms. Patty Ellaine E. Dela Cruz
9. Mr. Lorenzo Javier

C. END-USER REPRESENTATIVES:

- | | | | |
|----|-------------------------|---|----------------|
| 1. | Engr. Luzviminda Garcia | - | DPCB |
| 2. | Dr. Julie Mart Rubite | - | DPCB-LP and FP |
| 3. | Ms. Liezl Fernandez | - | DPCB-IDO |
| 4. | Ms. Jerisah Bernardo | - | DPCB-IDO |

D. PROSPECTIVE BIDDERS:

Project Title	Bidders' Representatives
Procurement of Betamethasone and Prednisone under IB No. 2020-068	a. Ms. Faith Garcillan – Bansan Pharma Distributor (BPD) b. Ms. Nancy Nuesca – AM Europharma Corporation (AMEC) c. Ms. Ruby Villanueva – Khriz Pharma (KP) d. Ms. Lodelyn Beligolo – Metro Drug, Inc. (MDI) e. Ms. Lalaine Rocero – Phil. Pharmawealth, Inc. (PPI) f. Ms. Flordeliza Abiog – Westfield Pharmaceuticals, Inc. (WPI) g. Mr. John Paul Alilino - Eliset Pharmaceutical, Inc. (EPI) h. Mr. Jeffrey Sinamban- SGS Healthcare Co. (SGSHC)
Procurement of Diloxanide under IB No. 2020-069	a. Ms. Faith Garcillan – BPD
Procurement of Fusidate Sodium/Fusidic Acid under IB No. 2020-070	a. Ms. Lodelyn Beligolo – MDI b. Ms. Nancy Nuesca – AMEC c. Ms. Lalaine Rocero – PPI d. Ms. Khristine Ocubillo – Eurocare Pharma, Inc. (EuPI) e. Ms. Ruby Villanueva – KP f. Mr. John Paul Alilino - EPI g. Ms. Flordeliza Abiog – WPI h. Mr. Jeffrey Sinamban- SGSHC
Procurement of Ketoconazole and Itraconazole under IB No. 2020-071	a. Ms. Lodelyn Beligolo – MDI b. Mr. Jeffrey Sinamban- SGSHC
Procurement of Oral Rehydration Salts under IB No. 2020-072	a. Ms. Lalaine Rocero –PPI b. Ms. Flordeliza Abiog – WPI
Procurement of Polysaccharide Polyvalent Pneumococcal Vaccine under IB No. 2020-040	a. Ms. Michelle Sanvictores – Zuellig Pharma Corp. (ZPC) b. Ms. Monaliza Rentoria- ZPC c. Ms. Carol Bayobos- ZPC d. Mr. Raphy Sanson- ZPC
Procurement of Influenza Polyvalent Vaccine under IB No. 2020-061	a. Mr. Joseph Victor Collado- ZPC b. Ms. Michelle Sanvictores –ZPC c. Ms. Monaliza Rentoria- ZPC d. Mr. Noriel Venerable- Sanofi e. Ms. Joan Torres- Sanofi f. Mr. Edwin Oblenida- Abbott

II. CALL TO ORDER

The Pre-bidding Conference for the Procurement of Various Drugs and Medicines and Vaccines for CY 2020 was called to order and presided over by Asec. Nestor F. Santiago, Jr., COBAC-A Chairperson on 20 November 2019, 10:00 AM at the COBAC Conference Room Ground Floor, Building 6, Department of Health (DOH).

III. MINUTES

The COBAC-A informed the Prospective Bidders (PBs) that they will first discuss the common requirements for the aforecited procurement projects and eventually go through the items for the discussion of the Total Approved Budget for the Contract (ABC), Schedule of Requirements and Technical Specifications.

1. The following subject matters were emphasized:
 - a) Section III. Bid Data Sheet including:
 - Eligibility Requirements
 - Technical Documents
 - Financial Requirements
 - Post-Qualification Requirements
 - b) Special Conditions of Contract under Section V of Bidding Documents
 - c) Schedule of Requirements under Section VI of Bidding Documents
 - d) Technical Specifications under Section VII of Bidding Documents
2. The following were the issues and concerns raised/discussed relative to Schedule of Requirements for the Procurement of Fusidate Sodium/Fusidic Acid under IB No. 2020-070:

Schedule of Requirements	
Particular	Query and Suggestion
<ul style="list-style-type: none"> Procurement of Fusidate Sodium/Fusidic Acid: Item No. 2 – Fusidate Sodium/Fusidic Acid Ointment. <p>Sixty (60) calendar days (cd) upon receipt of approved Notice to Proceed (NTP).</p>	<ul style="list-style-type: none"> MDI asked for the extension of Delivery Period from Sixty (60) to Ninety (90) cd upon receipt of approved NTP. The COBAC-A noted the request of MDI and informed that the said request will be forwarded to the End-user for confirmation.

3. The following were the issues and concerns raised/discussed relative to Schedule of Requirements and Technical Specifications and among others for the procurement of various vaccines, to wit:

Package Name	Particular	Query and/or Suggestion and Discussion
Procurement of Polysaccharide Polyvalent Pneumococcal Vaccine under IB No. 2020-040	<i>Sixty (60) calendar days from receipt of Notice to Proceed (NTP)</i>	<ul style="list-style-type: none"> The representative of ZPC requested for the extension of the delivery period to <i>Ninety (90)</i> calendar days (cd) from the receipt of the <i>approved</i> NTP. The End-user representative asked if it will be one-time delivery. The representative of ZPC said yes. The COBAC-A informed that the said request will be reviewed by the

		End-user.
	ABC: PhP201,200,000.00	<ul style="list-style-type: none"> The representative of ZPC said that they will submit a letter to the Committee requesting for an increase in the ABC due to inflation rate.
	<p>Shelf Life: Must be fresh commercial stock with a total shelf life of twenty four (24) months from the date of manufacture but not less than eighteen (18) months from the date of delivery.</p>	<ul style="list-style-type: none"> The representative of ZPC said that they had a hard time complying with the 18 months shelf life from the date of delivery for the last two (2) years. They will also write a letter to the Department of Health (DOH) regarding the shelf-life specification. The representative of ZPC requested changing the requirement to wit: <p>Shelf Life: Must be fresh commercial stock with a total shelf life of twenty four (24) months from the date of manufacture but not less than <i>fifteen (15)</i> months from the date of delivery.</p> The COBAC-A said that there is an issuance stating that products delivered below the standard shelf life or shelf life of less than twelve (12) months, the goods should be replaced. The End-user representative informed the COBAC-A that the said Administrative Order is not yet signed and approved. The COBAC-A noted the information.
Procurement of Influenza Polyvalent Vaccine under IB No. 2020-061	Quantity: 4,000,000 Doses	<ul style="list-style-type: none"> The representative of ZPC informed the Committee and the End-user representative on the production of trivalent versus quadrivalent flu vaccine. As of now, only few

		<p>countries are still using the trivalent flu vaccine. There is a chance that they will not be able to supply the required doses of 4,000,000. They can only provide 3,000,000 doses of trivalent flu vaccine.</p> <ul style="list-style-type: none"> • The representative of ZPC said that the strain for 2020 was only released by the World Health Organization (WHO) last September 2019. Upon computation, only 3,000,000 doses will be allocated to the Philippines. • The COBAC-A noted the information. • The Committee instructed the End-user to further review the requirement/specification. • The representative of Abbott asked if it will be possible for another company to provide the required volume of vaccine needed when the other company is not being able to supply the said quantity. • The COBAC-A Secretariat said that the procurement is through Public Bidding and the contract will be awarded to only one (1) supplier. • The representative of Abbott noted the information.
	Form & Strength: <ol style="list-style-type: none"> 1. 15 mcg/0.5mL 2. 0.5 ml multidose glass vial 	<ul style="list-style-type: none"> • The representative of Abbott requested to consider the pre-filled syringe. • The End-user representative said that the specifications stated in the bidding documents is based in Philippine National Formulary (PNF). • The End-user representative explained that the pre-filled syringe is not a World Health Organization

		<p>(WHO) pre-qualified.</p> <ul style="list-style-type: none"> The representative of Abbott said they check every year if the pre-filled syringe will be considered. The End-user representative said that the inclusion of the specifications in the PNF is through the DOH-Pharmaceutical Division (PD). The specifications used by the program is based on PNF and the PD cleared the specifications and price used by the program.
	<p>Valid and current Certificate of Product Registration (CPR) or Valid Extension issued by Philippine Food and Drugs Administration (PFDA) to be submitted before the release of the Notice of Award;</p> <p>Xxx</p>	<ul style="list-style-type: none"> The representative of ZPC clarify the specifications and requested the following: <ul style="list-style-type: none"> Form & Strength: <ol style="list-style-type: none"> 15 mcg/0.5mL <i>0.5 ml per dose</i> <i>5 ml</i> multidose glass vial The representative of ZPC said that every year, the vaccine will have a new submission of documents and registration to the Food and Drugs Administration (FDA). If we start the bidding by December, there is no CPR yet for the 2020 strain. They can only submit the old CPR which is valid until 2020. The representative of ZPC requested to change the requirement, to wit: <p>Valid and current Certificate of Product Registration (CPR) or Valid Extension issued by Philippine Food and Drugs Administration (PFDA) to be submitted before the release of the <i>Notice to Proceed</i>.</p> The COBAC-A Secretariat informed the representative of ZPC that before the release of NOA, the

		<p>documents of the winning bidder shall be complete and valid.</p> <ul style="list-style-type: none"> • The Committee asked if there is an exemption for the case of flu vaccine. The End-user representative said that the FDA has no exemption and usually the CPR with the new strain is released by April to May every year. Yearly there is a new strain for the flu vaccine and the FDA issue a new CPR for each new strain. • The End-user representative asked if in the law allow the submission of the new CPR upon receipt of the NTP. • The COBAC-A Secretariat said that they will verify to the Contract Management Division of the Procurement Service the said request if it is possible. • The COBAC-A Secretariat explained that the Procurement Service (PS) will only release the NOA to the winning bidder if all documents are complete and valid. • The representative of ZPC asked if it is acceptable to submit the proof of application for the new CPR for 2020 strain upon release of NOA. It is for the fast approval of the documents within the DOH and at the same time waiting for the release of the new CPR from the FDA. It is to prevent any further delay in the processing of documents. • The representative of ZPC said that if the CPR will be delayed for a month, it will also delay the process of the DOH. In the previous case, the CPR was submitted upon release of the NOA and then waited for the release of NTP. There was a
--	--	---


		<p>delay in the vaccination of the elderly considering that the flu vaccine shall be given before the rainy season.</p> <ul style="list-style-type: none"> • The End-user representative said that there will be no problem on their part with regards on the issue in the CPR. • The End-user representative asked if the law allow the release of NOA prior to the submission of the CPR for the 2020 strain of flu vaccine. The current CPR of the said vaccine is valid until June 2020. • The COBAC-A requested the bidder to write a letter regarding their requests for further review.
	<p><i>Fifteen (15) calendar days from receipt of Notice to Proceed (NTP)</i></p>	<ul style="list-style-type: none"> • The representative of ZPC asked if the delivery period can be changed to <i>Within ninety (90) calendar days from receipt of the approved Notice to Proceed (NTP).</i> • The COBAC-A Secretariat explained that the delivery of goods will start only upon release of the NTP. • The representative of ZPC noted the information. • The representative of ZPC asked if the delivery period can be changed to <i>Within thirty (30) calendar days (cd) from the receipt of the approved NTP.</i> • The COBAC-A said that the said request will be reviewed by the End-user.

4. The COBAC-A mentioned that should there be any more clarifications or inquiries after the issuance of Bid Bulletin, the bidders may send the COBAC-A Chairperson a formal letter at least ten (10) calendar days before the deadline set for the submission and receipt of bids.


IV. ADJOURNMENT

There having no other matters to discussed, the aforesaid meeting was adjourned at 11:00 AM.

Prepared by:


JANINE G. EUMAGUE
COBAC-A Secretariat

Approved by:


NESTOR F. SANTIAGO, JR., MD, MPH, MHS, CESO III
Assistant Secretary of Health
COBAC-A Chairperson